SAB Biotherapeutics, Inc. (SABS) Form 10-Q Quarterly Reports
SAB Biotherapeutics, Inc. (SABS) is a publicly traded company on the Nasdaq, categorized under SIC 2836 (Biological Products, (No Diagnostic Substances)). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: SABS
CIK: 1833214
Exchange: Nasdaq
SIC 2836: Biological Products, (No Diagnostic Substances)
Fiscal Year End: 12/31
State: DE
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
EisnerAmper LLP
Auditor SinceSince 12/31/2023 12:00:00 AM
Lead Engagement PartnerRichard Cleaveland
Audit LocationIselin, New Jersey, United States
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| 8-K | 2026-10-13 | 2026-10-13 | 8-K | 0001193125-26-419769 | View SEC Doc Filr Page |
| 4 | 2026-09-18 | 2026-09-17 | 4 | 0001193125-26-395552 | View SEC Doc Filr Page |
| 424B3 | 2026-08-21 | — | 424B3 | 0001193125-26-361180 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-08-14 | — | SCHEDULE 13G/A Filing | 0001193125-26-352646 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-08-14 | — | SCHEDULE 13G/A Filing | 0001727492-26-000022 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-08-14 | — | SCHEDULE 13G/A Filing | 0001831942-26-000035 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-08-14 | — | SCHEDULE 13G/A Filing | 0001213900-26-090054 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-08-14 | — | SCHEDULE 13G/A Filing | 0000919574-26-005263 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-08-14 | — | SCHEDULE 13G/A Filing | 0001172661-26-003437 | View SEC Doc Filr Page |
| SCHEDULE 13G | 2026-08-12 | — | SCHEDULE 13G Filing | 0000919574-26-004984 | View SEC Doc Filr Page |
| SCHEDULE 13D/A | 2026-08-10 | — | SCHEDULE 13D/A Filing | 0001346824-26-000220 | View SEC Doc Filr Page |
| 10-Q | 2026-08-06 | 2026-06-30 | 10-Q | 0001193125-26-336783 | View SEC Doc Filr Page |
| 8-K | 2026-07-07 | 2026-07-07 | 8-K | 0001193125-26-296936 | View SEC Doc Filr Page |
| 4 | 2026-06-26 | 2026-06-25 | 4 | 0001193125-26-285722 | View SEC Doc Filr Page |
| 8-K | 2026-06-18 | 2026-06-18 | 8-K | 0001193125-26-275976 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-05-15 | — | SCHEDULE 13G/A Filing | 0001193125-26-226560 | View SEC Doc Filr Page |
| SCHEDULE 13G | 2026-05-15 | — | SCHEDULE 13G Filing | 0001727492-26-000011 | View SEC Doc Filr Page |
| SCHEDULE 13G | 2026-05-15 | — | SCHEDULE 13G Filing | 0001193125-26-225169 | View SEC Doc Filr Page |
| 10-Q | 2026-05-12 | 2026-03-31 | 10-Q | 0001193125-26-218195 | View SEC Doc Filr Page |
| 8-K | 2026-05-04 | 2026-04-28 | 8-K | 0001193125-26-204125 | View SEC Doc Filr Page |
| SCHEDULE 13G | 2026-05-01 | — | SCHEDULE 13G Filing | 0001104659-26-054220 | View SEC Doc Filr Page |
| DEF 14A | 2026-04-30 | 2026-06-18 | DEF 14A | 0001193125-26-197607 | View SEC Doc Filr Page |
| 8-K | 2026-04-22 | 2026-04-22 | 8-K | 0001193125-26-168569 | View SEC Doc Filr Page |
| S-8 | 2026-03-31 | — | S-8 | 0001193125-26-134733 | View SEC Doc Filr Page |
| 4 | 2026-03-25 | 2026-03-24 | 4 | 0001193125-26-124231 | View SEC Doc Filr Page |